https://www.macrotrends.net/stocks/charts/GNMSF/genmab/eps-earnings-per-share-diluted
Genmab eps - earnings per share from 2012 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common...
earnings per sharegenmabeps
https://www.industryweek.com/expansion-management/article/21958112/johnson-johnson-inks-11-billion-deal-with-genmab
Unit of J&J will be granted license to develop and commercialize Daratumumab, which is used to treat multiple myeloma, a type of bone marrow cancer.
johnsoninksbilliondealgenmab
https://www.techtarget.com/pharmalifesciences/news/366607609/AbbVie-Genmab-Team-Up-for-Antibody-Therapeutics-for-Cancer
AbbVie and Genmab sign a collaborative agreement to maximize the development of promising early-stage antibody therapeutics to bring potential treatments to...
team upantibody therapeuticsabbviegenmabcancer
https://www.macrotrends.net/stocks/charts/GNMSF/genmab/net-profit-margin
Genmab net profit margin from 2012 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
net profit margingenmab
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-amendment-to-ofatumumab-agreement/
GSK and GEN announced today an amendment to the ofatumumab co-development and commercialisation agreement.
glaxosmithklinegenmabannounceamendmentofatumumab
https://www.marketscreener.com/news/abbvie-genmab-lymphoma-treatment-shows-improved-progression-free-survival-ce7e58dfd88af421
By Kelly Cloonan Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in...
progression free survivalabbviegenmablymphomatreatment